FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020969673> ?p ?o ?g. }

• W2020969673 endingPage "1911" @default.
• W2020969673 startingPage "1904" @default.
• W2020969673 abstract "Background. Continuous local delivery of interleukin-2 (IL-2) and interferon-alpha (IFN-α) via gene transfer appears to be more effective than systemic therapy in preventing the growth of human renal cell carcinoma (RCC) in vitro and in vivo. To understand further if cytokine-gene transfection of RCC could alter certain cellular properties that are associated with the Invasive and metastatic potentials of tumor, the authors characterized six cell lines that produce IL-2 and/or IFN-α in their expression of intercellular adhesion molecule-1 (ICAM-1) and CD44; binding affinity to extracellular matrix (ECM) components (fibronectin, laminin, type IV collagen, and vitronectin); and preference in forming homotypic aggregation and mRNA levels of c-myc, epidermal growth factor receptor (EGF-R), tumor transforming growth factor-β (TGF-β) and type IV collagenase. These six lines were compared with control vector transfected parental R11 line. Methods. The expression of ICAM-1 and CD44 was determined by fluorescence-activated cell sorter (FACS) analysis, the tumor cell binding affinity to ECM components was measured by cell attachment assay, the degree of homotypic aggregation was quantified by cell aggregation assay, and the mRNA levels of c-myc, EGF-R, TGF-β, and collagenase were analyzed by a quantitative polymerase chain reaction analysis. Results. Both IL-2-gene- and IFN-β-gene-modified R11 exhibited enhanced expression of ICAM-1, suppression of CD44, and decreased binding affinity to ECM components, when compared with the R11-control vector. All cytokine-producing tumor lines showed a decreased preference to form homotypic aggregation. Interferon-alpha gene transfer downregulated c-myc, EGF-R, and type IV collagenase mRNA expression, whereas only the higher producers of IL-2 downregulated TGF-β mRNA expression. Exogenous IL-2 and/or IFN-α treatment of a IFN-α-resistant RCC enhanced both HLA class I antigen and ICAM-1 expression and suppressed CD44 expression, but had no effect on tumor growth rate. Conclusions. The local production of high concentrations of IL-2 and IFN-a at the tumor site may directly alter tumor properties associated with invasive and metastatic phenotypes of RCC. Interleukin-2 and/or IFN-α gene therapy may be an effective strategy for treatment of patients with advanced renal cancer." @default.
• W2020969673 created "2016-06-24" @default.
• W2020969673 creator A5013867374 @default.
• W2020969673 creator A5016421972 @default.
• W2020969673 creator A5029872821 @default.
• W2020969673 creator A5034963668 @default.
• W2020969673 creator A5047715537 @default.
• W2020969673 creator A5050649350 @default.
• W2020969673 creator A5065715350 @default.
• W2020969673 creator A5087322472 @default.
• W2020969673 date "1994-10-01" @default.
• W2020969673 modified "2023-10-02" @default.
• W2020969673 title "In vitro modulation of the invasive and metastatic potentials of human renal cell carcinoma by interleukin-2 and/or interferon-alpha gene transfer" @default.
• W2020969673 cites W1904017285 @default.
• W2020969673 cites W1912348852 @default.
• W2020969673 cites W1975568557 @default.
• W2020969673 cites W1984127506 @default.
• W2020969673 cites W1985585224 @default.
• W2020969673 cites W1986400155 @default.
• W2020969673 cites W2013524931 @default.
• W2020969673 cites W2019405807 @default.
• W2020969673 cites W2025572360 @default.
• W2020969673 cites W2067374202 @default.
• W2020969673 cites W2084162026 @default.
• W2020969673 cites W2087117588 @default.
• W2020969673 cites W2096982903 @default.
• W2020969673 cites W2117837558 @default.
• W2020969673 cites W2138463196 @default.
• W2020969673 cites W2145388051 @default.
• W2020969673 cites W4294216491 @default.
• W2020969673 doi "https://doi.org/10.1002/1097-0142(19941001)74:7<1904::aid-cncr2820740713>3.0.co;2-b" @default.
• W2020969673 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7521786" @default.
• W2020969673 hasPublicationYear "1994" @default.
• W2020969673 type Work @default.
• W2020969673 sameAs 2020969673 @default.
• W2020969673 citedByCount "30" @default.
• W2020969673 countsByYear W20209696732012 @default.
• W2020969673 countsByYear W20209696732020 @default.
• W2020969673 countsByYear W20209696732022 @default.
• W2020969673 crossrefType "journal-article" @default.
• W2020969673 hasAuthorship W2020969673A5013867374 @default.
• W2020969673 hasAuthorship W2020969673A5016421972 @default.
• W2020969673 hasAuthorship W2020969673A5029872821 @default.
• W2020969673 hasAuthorship W2020969673A5034963668 @default.
• W2020969673 hasAuthorship W2020969673A5047715537 @default.
• W2020969673 hasAuthorship W2020969673A5050649350 @default.
• W2020969673 hasAuthorship W2020969673A5065715350 @default.
• W2020969673 hasAuthorship W2020969673A5087322472 @default.
• W2020969673 hasBestOaLocation W20209696731 @default.
• W2020969673 hasConcept C1491633281 @default.
• W2020969673 hasConcept C153911025 @default.
• W2020969673 hasConcept C164144092 @default.
• W2020969673 hasConcept C189165786 @default.
• W2020969673 hasConcept C203014093 @default.
• W2020969673 hasConcept C2778690821 @default.
• W2020969673 hasConcept C2780932548 @default.
• W2020969673 hasConcept C502942594 @default.
• W2020969673 hasConcept C54009773 @default.
• W2020969673 hasConcept C54355233 @default.
• W2020969673 hasConcept C55493867 @default.
• W2020969673 hasConcept C81885089 @default.
• W2020969673 hasConcept C86492073 @default.
• W2020969673 hasConcept C86803240 @default.
• W2020969673 hasConcept C95444343 @default.
• W2020969673 hasConceptScore W2020969673C1491633281 @default.
• W2020969673 hasConceptScore W2020969673C153911025 @default.
• W2020969673 hasConceptScore W2020969673C164144092 @default.
• W2020969673 hasConceptScore W2020969673C189165786 @default.
• W2020969673 hasConceptScore W2020969673C203014093 @default.
• W2020969673 hasConceptScore W2020969673C2778690821 @default.
• W2020969673 hasConceptScore W2020969673C2780932548 @default.
• W2020969673 hasConceptScore W2020969673C502942594 @default.
• W2020969673 hasConceptScore W2020969673C54009773 @default.
• W2020969673 hasConceptScore W2020969673C54355233 @default.
• W2020969673 hasConceptScore W2020969673C55493867 @default.
• W2020969673 hasConceptScore W2020969673C81885089 @default.
• W2020969673 hasConceptScore W2020969673C86492073 @default.
• W2020969673 hasConceptScore W2020969673C86803240 @default.
• W2020969673 hasConceptScore W2020969673C95444343 @default.
• W2020969673 hasIssue "7" @default.
• W2020969673 hasLocation W20209696731 @default.
• W2020969673 hasLocation W20209696732 @default.
• W2020969673 hasOpenAccess W2020969673 @default.
• W2020969673 hasPrimaryLocation W20209696731 @default.
• W2020969673 hasRelatedWork W1485588301 @default.
• W2020969673 hasRelatedWork W2040998738 @default.
• W2020969673 hasRelatedWork W2053393868 @default.
• W2020969673 hasRelatedWork W2163799657 @default.
• W2020969673 hasRelatedWork W2347120132 @default.
• W2020969673 hasRelatedWork W2364319975 @default.
• W2020969673 hasRelatedWork W2368480016 @default.
• W2020969673 hasRelatedWork W2379152510 @default.
• W2020969673 hasRelatedWork W2384261171 @default.
• W2020969673 hasRelatedWork W2462877824 @default.
• W2020969673 hasVolume "74" @default.
• W2020969673 isParatext "false" @default.
• W2020969673 isRetracted "false" @default.
• W2020969673 magId "2020969673" @default.

• next